Clinuvel Pharmaceuticals Limited
CLVLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $59 | $36 | $56 | $33 |
| % Growth | 66.5% | -36.3% | 70.5% | – |
| Cost of Goods Sold | $19 | $3 | $15 | $15 |
| Gross Profit | $41 | $33 | $41 | $17 |
| % Margin | 68.4% | 91.4% | 73.3% | 51.6% |
| R&D Expenses | $5 | $3 | $2 | $1 |
| G&A Expenses | $26 | $0 | $1 | $0 |
| SG&A Expenses | $9 | $13 | $14 | $5 |
| Sales & Mktg Exp. | $0 | $12 | $13 | $4 |
| Other Operating Expenses | $0 | $0 | -$7 | $0 |
| Operating Expenses | $14 | $16 | $9 | $6 |
| Operating Income | $27 | $17 | $32 | $14 |
| % Margin | 45.4% | 47.4% | 57.6% | 44.1% |
| Other Income/Exp. Net | $3 | $5 | $4 | $0 |
| Pre-Tax Income | $30 | $22 | $36 | $15 |
| Tax Expense | $8 | $8 | $11 | $4 |
| Net Income | $22 | $14 | $25 | $11 |
| % Margin | 37.2% | 39.5% | 44.2% | 33.3% |
| EPS | 0.44 | 0.28 | 0.49 | 0.22 |
| % Growth | 57.1% | -42.9% | 122.7% | – |
| EPS Diluted | 0.44 | 0.28 | 0.49 | 0.21 |
| Weighted Avg Shares Out | 50 | 50 | 51 | 50 |
| Weighted Avg Shares Out Dil | 50 | 50 | 50 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $3 | $4 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $1 |
| EBITDA | $30 | $17 | $35 | $21 |
| % Margin | 50.9% | 47.4% | 62.3% | 65.3% |